211 related articles for article (PubMed ID: 27322484)
1. News on the medical treatment of young women with early-stage HER2-negative breast cancer.
Lambertini M; Poggio F; Vaglica M; Blondeaux E; Del Mastro L
Expert Opin Pharmacother; 2016 Aug; 17(12):1643-55. PubMed ID: 27322484
[TBL] [Abstract][Full Text] [Related]
2. Ovarian Function Suppression in Premenopausal Women with Early-Stage Breast Cancer.
Lambertini M; Del Mastro L; Viglietti G; Pondé NF; Solinas C; de Azambuja E
Curr Treat Options Oncol; 2017 Jan; 18(1):4. PubMed ID: 28185173
[TBL] [Abstract][Full Text] [Related]
3. Luteininzing hormone releasing hormones analogs in combination with tamoxifen for the adjuvant treatment of premenopausal women with hormone receptor positive breast cancer.
Conte B; Poggio F; Del Mastro L
Expert Opin Pharmacother; 2017 Sep; 18(13):1357-1362. PubMed ID: 28764603
[TBL] [Abstract][Full Text] [Related]
4. The Evolving Complexity of Treating Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer: Special Considerations in Older Breast Cancer Patients-Part I: Early-Stage Disease.
Sammons S; Sedrak MS; Kimmick GG
Drugs Aging; 2020 May; 37(5):331-348. PubMed ID: 32100240
[TBL] [Abstract][Full Text] [Related]
5. The curability of breast cancer and the treatment of advanced disease.
Guarneri V; Conte PF
Eur J Nucl Med Mol Imaging; 2004 Jun; 31 Suppl 1():S149-61. PubMed ID: 15107948
[TBL] [Abstract][Full Text] [Related]
6. Luteinizing hormone-releasing hormone agonists in premenopausal hormone receptor-positive breast cancer.
Tan SH; Wolff AC
Clin Breast Cancer; 2007 Feb; 7(6):455-64. PubMed ID: 17386122
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant endocrine therapy for premenopausal women with hormone-responsive breast cancer.
Mathew A; Davidson NE
Breast; 2015 Nov; 24 Suppl 2():S120-5. PubMed ID: 26255743
[TBL] [Abstract][Full Text] [Related]
8. Clinical Outcomes in Early Breast Cancer With a High 21-Gene Recurrence Score of 26 to 100 Assigned to Adjuvant Chemotherapy Plus Endocrine Therapy: A Secondary Analysis of the TAILORx Randomized Clinical Trial.
Sparano JA; Gray RJ; Makower DF; Albain KS; Saphner TJ; Badve SS; Wagner LI; Kaklamani VG; Keane MM; Gomez HL; Reddy PS; Goggins TF; Mayer IA; Toppmeyer DL; Brufsky AM; Goetz MP; Berenberg JL; Mahalcioiu C; Desbiens C; Hayes DF; Dees EC; Geyer CE; Olson JA; Wood WC; Lively T; Paik S; Ellis MJ; Abrams J; Sledge GW
JAMA Oncol; 2020 Mar; 6(3):367-374. PubMed ID: 31566680
[TBL] [Abstract][Full Text] [Related]
9. An Italian Delphi study to evaluate consensus on adjuvant endocrine therapy in premenopausal patients with breast cancer: the ERA project.
Pelizzari G; Arpino G; Biganzoli L; Cinieri S; De Laurentiis M; Del Mastro L; Di Leo A; Gori S; Guarneri V; Marchetti P; Puglisi F
BMC Cancer; 2018 Sep; 18(1):932. PubMed ID: 30261866
[TBL] [Abstract][Full Text] [Related]
10. Optimal adjuvant endocrine therapy for early breast cancer.
Stuart-Harris R; Davis A
Womens Health (Lond); 2010 May; 6(3):383-98. PubMed ID: 20426605
[TBL] [Abstract][Full Text] [Related]
11. Optimal systemic therapy for premenopausal women with hormone receptor-positive breast cancer.
Jankowitz RC; McGuire KP; Davidson NE
Breast; 2013 Aug; 22 Suppl 2():S165-70. PubMed ID: 24074781
[TBL] [Abstract][Full Text] [Related]
12. European oncologists' preferences for the management of breast cancer: case presentations and expert commentary.
Anderssona M; Awadab A; Barrett-Leec P; Ellisd P; Hupperetse P; Jackischf C; Kubistag E; Lückh HJ; Monnerati C; Nitzj U; Untchl M
Breast; 2008 Feb; 17 Suppl 2():S1-S12. PubMed ID: 18439963
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant endocrine therapy for premenopausal women: Type and duration.
Francis PA
Breast; 2017 Aug; 34 Suppl 1():S108-S111. PubMed ID: 28669713
[TBL] [Abstract][Full Text] [Related]
14. Breast cancer: achievements in adjuvant systemic therapies in the pre-genomic era.
Colozza M; de Azambuja E; Cardoso F; Bernard C; Piccart MJ
Oncologist; 2006 Feb; 11(2):111-25. PubMed ID: 16476832
[TBL] [Abstract][Full Text] [Related]
15. [Standards, Options and Recommendations (SOR) for endocrine therapy in patients with non metastatic breast cancer. FNCLCC].
Mauriac L; Blanc-Vincent MP; Luporsi E; Cutuli B; Fourquet A; Garbay JR; Giard S; Spyratos F; Zafrani B; Dilhuydy JM
Bull Cancer; 2000 Jun; 87(6):469-90. PubMed ID: 10903789
[TBL] [Abstract][Full Text] [Related]
16. [Sensitivity of chemotherapy depending on hormone status in breast cancer].
Ito Y
Nihon Rinsho; 2007 Jun; 65 Suppl 6():568-71. PubMed ID: 17679212
[No Abstract] [Full Text] [Related]
17. [Adjuvant chemotherapy of early stage breast cancer].
Boér K
Orv Hetil; 2010 Feb; 151(9):344-53. PubMed ID: 20159750
[TBL] [Abstract][Full Text] [Related]
18. Progress in systemic chemotherapy of primary breast cancer: an overview.
Hortobagyi GN
J Natl Cancer Inst Monogr; 2001; (30):72-9. PubMed ID: 11773296
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant therapy for premenopausal patients with early breast cancer.
Kurebayashi J
Curr Opin Obstet Gynecol; 2008 Feb; 20(1):51-4. PubMed ID: 18197006
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant hormonal therapy for premenopausal women with breast cancer.
Emens LA; Davidson NE
Clin Cancer Res; 2003 Jan; 9(1 Pt 2):486S-94S. PubMed ID: 12538505
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
